Cargando empresa
Just reported
Q3 2026 results
From Immunitybio's results release of 9 de noviembre de 2026; its quarterly report has since been filed.
Revenue
Actual
48,8M US$
+52 % y/y
-4,7 % q/qGuided
—
No guide given
EPS, GAAP
Actual
-0,18 US$
Guided
—
No guide given
Operating income, GAAP
Actual
-78M US$
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Immunitybio is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B US$A+
EXELExelixis, Inc.17B US$A+
JAZZJazz Pharmaceuticals plc15,4B US$A
HALOHalozyme Therapeutics, Inc.11,5B US$A+
TECHBIO-Techne Corp11,4B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 oct 2026BAGraded B, now A
Estados financieros completos →
Construido a partir de los propios informes de Immunitybio, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
